Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B‐cell lymphomas
Sign Up to like & getrecommendations! Published in 2021 at "Hematological Oncology"
DOI: 10.1002/hon.2871
Abstract: Bendamusutine plus rituximab (BR) regimen is one of the standard regimens for indolent B‐cell lymphomas, yet the possibility of reduction of cycles of BR therapy without compromising therapeutic effects is not still uncovered. We retrospectively… read more here.
Keywords: response; indolent cell; cell lymphomas; reduction cycles ... See more keywords